University of Groningen
ADPKD
Messchendorp, Annemarie Lianne
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Messchendorp, A. L. (2019). ADPKD: Risk Prediction for Treatment Selection. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
290
A. Lianne Messchendorp, Bart J. Kramers, Edwin M. Spithoven, Katrin Stade,
Esther Meijer and Ron T. Gansevoort, on behalf of the DIPAK Consortium. Effect of a somatostatin analogue on the vasopressin pathway in patients with autosomal dominant polycystic kidney disease. Submitted
A. Lianne Messchendorp, Esther Meijer, Folkert W. Visser, Gerwin E. Engels, Peter
Kappert, Monique Losekoot, Dorien J.M. Peters and Ron T. Gansevoort, on behalf of the DIPAK Consortium. Urinary biomarkers to select patients with rapidly progressive autosomal dominant polycystic kidney disease. Submitted
A. Lianne Messchendorp, Niek F. Casteleijn, Joost P. Drenth, Johan W. de Fijter, Dorien
J.M. Peters, Folkert W. Visser, Jack F. Wetzels, Robert Zietse, Esther Meijer and Ron T. Gansevoort, on behalf of the DIPAK Consortium. Somatostatin in renal physiology and the place of somatostatin analogues in autosomal dominant polycystic kidney disease. Submitted
Rene M.M. van Aerts, Wietske Kievit, Hedwig M.A. D’Agnolo, Charles J. Blijdorp, Niek F. Casteleijn, Shosha E.I. Dekker, Johan W. de Fijter, Maatje D.A. van Gastel, Tom J. Gevers, Liyanne F.M., van de Laarschot, Marten A. Lantinga, Monique Losekoot, Esther Meijer,
A. Lianne Messchendorp, Myrte K. Neijenhuis, Michelle J. Pena, Dorien J.M. Peters,
Mahdi Salih, Darius Soonawala, Edwin M. Spithoven, Folkert W. Visser, Jack F. Wetzels, Robert Zietse, Ron T. Gansevoort and Joost P.H. Drenth, for the DIPAK-1 Investigators. Lanreotide reduces liver growth in autosomal dominant polycystic kidney disease: data from a 120-week randomized clinical trial. Submitted
A. Lianne Messchendorp, Edwin M. Spithoven, Niek F. Casteleijn, Wendy Dam, Jacob
van den Born, Wouter F. Tonnis, Carlo A.J.M. Gaillard and Esther Meijer. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrology. 2018 Dec
Esther Meijer, Folkert W. Visser, Rene M.M. van Aerts, Charles J. Blijdorp, Niek F. Casteleijn, Hedwig M.A. D’Agnolo, Shosha E.I. Dekker, Joost P.H. Drenth, Johan W. de Fijter, Maatje D.A. van Gastel, Tom J. Gevers, Marten A. Lantinga, Monique Losekoot,
A. Lianne Messchendorp, Myrte K. Neijenhuis, Michelle Pena, Dorien J.M. Peters,
Mahdi Salih, Darius Soonawala, Edwin M. Spithoven, Jack F Wetzels, Robert Zietse, Ron T Gansevoort, for the DIPAK-1 investigators. Effect of lanreotide on kidney function in
List of publications
patients with autosomal dominant polycystic kidney disease. The DIPAK 1 randomized clinical trial. JAMA. 2018 Nov
A. Lianne Messchendorp, Marco van Londen, Jacob M. Taylor, Martin H. de Borst,
Gerjan Navis, Niek. F. Casteleijn, Carlo A.J.M. Gaillard, Stephan, J.L. Bakker and Ron T. Gansevoort, on behalf of the DIPAK consortium. Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease. Clin J Am Soc
Nephrol. 2018 Sep
Marco van Londen, Nicolien Kasper, Niek R. Hessels, A. Lianne Messchendorp, Stephan
J.L. Bakker, Jan-Stephan Sanders, Stefan P. Berger, Martin H. de Borst and Gerjan Navis. Renal functional reserve capacity before and after living kidney donation. Am
J Physiol Renal Physiol. 2018 Aug
Xiaochen Chen, Jin Ma, Tony Kwan, Elisabeth Stribos, A. Lianne Messchendorp, Yik
Loh, Xiaoyu Wang, Moumita Paul, Eithne Cunningham, Miriam Habib, Ian Alexander, Alexandra Sharland, Steve Chadban and Huiling Wu. Blockade of HMGB1 Attenuates Diabetic Nephropahty in Mic. Nature Sci Rep. 2018 May
A. Lianne Messchendorp, Esther Meijer, Wendy E. Boertien, Gerwin E. Engels, Niek
F. Casteleijn, Edwin M. Spithoven, Monique Losekoot, Johannes G.M. Burgerhof, Dorien J.M. Peters and Ron T. Gansevoort, on behalf of the DIPAK Consortium. Urinary biomarkers to identity ADPKD patients with a high likelihood of disease progression.
Kidney Int Rep. 2017 Oct
Hedwig M.A. d’Agnolo, Niek F. Casteleijn, Tom J.G. Gevers, Johan W. de Fijter, Maatje D.A. van Gastel, A. Lianne Messchendorp, Dorien J.M. Peters, Mahdi Salih, Darius
Soonawala, Edwin M. Spithoven, Folkert W. Visser, Jack F.M. Wetzels, Robert Zietse, Ron T. Gansevoort and Joost P.H. Drenth. The association of combined total kidney and liver volume with pain and gastrointestinal symptoms in patients with later stage autosomal dominant polycystic kidney disease. Am J Nephrol. 2017 Sep
A. Lianne Messchendorp, Maatje D.A. van Gastel, Peter Kappert, Merel A. Kaatee,
Marissa de Jong, Remco J. Renken, Gert Jan ter Horst, Shekar V.K. Mahesh and Ron T. Gansevoort. T1 vs. T2 weighted magnetic resonance imaging to assess total kidney
292
volume in patients with autosomal dominant polycystic kidney disease. Abdom Radiol.
2018 May
Marten A. Lantinga, Hedwig M. D’Agnolo, Niek F. Casteleijn, Johan W. de Fijter, Esther Meijer, A. Lianne Messchendorp, Dorien J.M. Peters, Mahdi Salih, Edwin M. Spithoven,
Darius Soonawala, Folkert W. Visser, Jack F. Wetzels, Robert Zietse, Joost P. Drenth and Ron T. Gansevoort, on behalf of the DIPAK consortium. Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: An interim analysis of the randomized open-label multicenter DIPAK-1 study. Drug Saf. 2017 Feb
Niek F. Casteleijn, A. Lianne Messchendorp, Kyong T. Bae, Eiji Higashihara, Peter
Kappert, Vicente Torres, Esther Meijer and Anna M. Leliveld. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clin Exp Nephrol. 2017 Jun
Edwin M. Spithoven, A. Lianne Messchendorp, Maatje D.A. van Gastel, Niek F.
Casteleijn, Joost P. Drenth, Carlo A.J.M. Gaillard, Johan W. de Fijter, Esther Meijer, Dorien J.M. Peters, Peter Kappert, Remco J. Renken, Folkert W. Visser, Jack F. Wetzels, Robert Zietse and Ron T.Gansevoort, on behalf of the DIPAK consortium. Estimation of total kidney volume in autosomal dominant polycystic kidney disease. Am J Kidney
Dis. 2015 Nov
A. Lianne Messchendorp and Ron T. Gansevoort. Blood pressure in early autosomal
dominant polycystic kidney disease. N Engl J Med. 2015 Mar
